Brief: Shuttle Pharma Completes Clinical Trial Site Enrollment For Phase 2 Of Ropidoxuridine For Treatment Of Patients With Glioblastoma
28/10/2024 21:29
Oct 28 (Reuters) - Shuttle Pharmaceuticals Holdings Inc
SHPH.O :
* SHUTTLE PHARMA COMPLETES CLINICAL TRIAL SITE ENROLLMENT
FOR
PHASE 2 OF ROPIDOXURIDINE FOR TREATMENT OF PATIENTS WITH
GLIOBLASTOMA
* SHUTTLE PHARMACEUTICALS HOLDINGS INC - TRIAL EXPECTED TO
BE
COMPLETED IN 18-24 MONTHS
Source text: ID:nGNX8R1KpK
Further company coverage: SHPH.O
((reuters.briefs@thomsonreuters.com;))